Navigation Links
Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
Date:5/13/2009

ther group (P=0.006). The percentage of Osteoarthritis Research Society International (OARSI) responders for the EUFLEXXA(R) group was also significantly greater than that in the other group (67% versus 59% (P=0.047). A subject is considered a responder if there is a high improvement in pain or function, or improvement in at least two of the following three categories: pain greater than or equal to 20% and absolute change greater than or equal to 10 mm, function greater than or equal to 20% and absolute change greater than or equal to 10 mm, and/or patient global assessment greater than or equal to 20% and absolute change.

About EUFLEXXA(R)

EUFLEXXA(R) (1% sodium hyaluronate) is the first non-avian derived* hyaluronic acid (HA) approved in the U.S. for treatment of knee pain due to osteoarthritis (OA). EUFLEXXA(R) is indicated for patients who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. The process used to manufacture EUFLEXXA(R) results in highly-purified HA with properties similar to the HA in healthy human synovial fluid.(2-4) EUFLEXXA(R) received approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit www.EUFLEXXA.com.

EUFLEXXA(R) should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site. Common adverse events reported were arthralgia (joint pain) and back pain. Temporary knee pain and swelling may occur after injection. Strict aseptic technique must be followed to avoid joint infection.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmac
'/>"/>

SOURCE Ferring Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
2. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015  Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) will ... on Wednesday, May 6, 2015, following the close of the ... conference call and live webcast on the same day at ... discuss the financial results.  To access the ... the "Investors" link.  Please log onto the webcast prior to ...
(Date:4/16/2015)... Kenneth C. Frazier , chairman and chief executive officer ... the Board of the Pharmaceutical Research and Manufacturers of America ... John J. Castellani announced that he will be retiring ... to PhRMA Board Frazier formerly held the position ... and CEO of Pfizer, Inc. Also elected were George ...
(Date:4/16/2015)... YORK , April 16, 2015 An ... additional way to generate trimers from the major HIV ... could benefit future clinical development of HIV vaccine candidates ... the critical target on the surface of HIV for ... an important platform for AIDS vaccine discovery, says ...
Breaking Medicine Technology:Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 2Alexza to Report 2015 First Quarter Financial Results and Provide Corporate Update on Wednesday, May 6, 2015 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5New Method Holds Promise for HIV Vaccine Development 2
... Corporation (Nasdaq: GNBT, www.generex.com ), the leader in ... of the mouth, today announced that it has been ... Canadian Intellectual Property Office granted Canadian Patent No. 2,401,942, ... Application". This new patent increases the number ...
... International Corporation (Nasdaq: PRXL ) announced today it ... Conference in New York.  James Winschel, Senior Vice President and ... at 11:45 a.m. ET on Tuesday, October 5, 2010. ... through the "Investors" section of PAREXEL,s website at ...
Cached Medicine Technology:Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 2Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System 3PAREXEL International to Present at William Blair Emerging Growth Stock Conference 2
(Date:4/19/2015)... The American Institute for Cancer Research (AICR) ... to host its second annual, nationwide Shred Cancer event. ... in order to raise funds for cancer research and ... event is being held at 20+ PROSHRED locations throughout ... time will vary at select locations. , Individuals are ...
(Date:4/19/2015)... WI (PRWEB) April 19, 2015 HealthPostures, ... announces that it will exhibit it’s pioneering ergonomics ... Expo and the Iowa-Illinois Safety Council Professional Development Conference ... and the TaskMate EZ are used in volume by ... facilities. , Built to clamp to a desk, ...
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog ... cheaper during Spring. , Spring can be a ... should make sure they compare the newest policies before ... learn more about Spring car insurance offers by reading ... quotes are becoming more and more popular. Many insurance ...
(Date:4/18/2015)... has released a new blog post explaining how to ... Clients can review important auto insurance quotes online, by ... advantages for clients who need affordable financial security for ... coverage for their vehicles can purchase a policy at ... agencies offer important discounts and drivers can learn more ...
(Date:4/18/2015)... the past few weeks, TheBeautyPlace.com has been undergoing maintenance ... run maintenance on our shipping facilities to update software ... Director. "It disrupted our regular shipping schedule but we ... track after having completed the maintenance." , Now, TheBeautyPlace.com ... has not allowed some calls to come in through ...
Breaking Medicine News(10 mins):Health News:2015 Annual Nationwide "Shred Cancer" Shredding Event 2Health News:HealthPostures' TaskMate Products to be Exhibited at the Wisconsin and Iowa-Illinois Safety Conferences 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2Health News:TheBeautyPlace.com Temporary Number Available 2
... poor, has banned the life-threatening practice of female circumcision, the ... in female genital mutilation (FGM) would be punished with a ... follows a campaign against the practice by the National Union ... women are circumcised. ,'Female circumcision is a ...
... of a Canadian university have voted overwhelmingly to remove ... company has implemented// unethical practices in India and Colombia. ... University of Guelph voted last week to remove Coca-Cola ... to India Resource Center, an international campaigning organization that ...
... the developing world? Look at Galway, the third largest city in ... Scores of people have taken ill and tens of thousands are ... ,Water supply in Galway has been hit by an outbreak of ... to have been hit by a serious stomach bug as a ...
... company, Crucell N V’s Rabies monoclonal antibody (mAb) product ... four months after launching// a similar study in the ... monoclonal antibody product for the post-exposure prophylaxis of rabies, ... phase I study is closely linked to the initial ...
... of low-sugar potato, as there is an increasing demand across ... trend is particularly evident in Gujarat in western India, where ... to the new variety. ,The low-sugar potato is ... processing firms snap up the produce without any delay, farmers ...
... major, Intercell and its partner Hyderabad-based Biological E. ... to start// a pediatric phase II clinical trial ... ,The randomized and controlled study aims ... Intercell’s JE vaccine compared to a locally produced ...
Cached Medicine News:Health News:Eritrea Bans Female Circumcision 2Health News:Water Crisis Wreaks Havoc on Irish City 2Health News:Crucell's Rabies MAb Enters Phase I Trial in India 2
Micro-hematocrit tubes available in multiple sizes and additives for a wide range of capillary blood collection....
... The Vivid 3 system is designed ... of cardiovascular performance, and offer an even ... pediatrics and the OR. From color flow ... connectivity, the new Vivid 3 offers a ...
... 4 system is an easy-to-use, high-performance ultrasound ... your clinical practice. In effect, GE has ... a value-based combination of proven technology and ... paid heed to features praised by Vivid ...
... remote monitoring from Medtronic is changing the ... care. Using their Medtronic CareLink Monitor and ... send device information from their home or ... site, clinicians have the ability to review ...
Medicine Products: